Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Dr. Grinspoon, MD

Advisor

Dr. Steven K. Grinspoon Photo
Dr. Grinspoon is a Professor of Medicine, Harvard Medical School, Chief of the MGH Metabolism Unit, Director of the Nutrition Obesity Research Center at Harvard and Endowed Chair in Neuroendocrinology and Metabolism. He has had a long-standing interest in the metabolic complications and regulation of ectopic adipose tissue in obesity and lipodystrophic conditions, with a specific focus on HIV lipodystrophy. He has served on the World Health Organization Technical Advisory Group on Nutrition in HIV Disease and Chaired the American Heart Association State of the Science Conference on Cardiovascular Disease in HIV-infected patients, as well as a recent NIH-sponsored conference on the mechanisms and complications of obesity in HIV-infected patients. In his research, he has investigated the effects of reduced pulsatile growth hormone secretion on metabolic dysregulation in obesity and was the first to propose the use of a GHRH analogue to increase endogenous GH secretion in lipodystrophy and generalized obesity. This strategy has shown that augmentation of endogenous GH pulsatility selectively reduces visceral fat, improves carotid IMT, and reduces inflammatory indices. This work led to the FDA approval of Tesamorelin for excess visceral fat accumulation in HIV-infected patients. For his work Dr. Grinspoon was awarded the 2016 Aurbach Laureate award in translational research from the Endocrine Society. More recently he has shown beneficial effects of Tesamorelin on liver fat and fibrosis progression among HIV-infected patients with nonalcoholic fatty liver disease. He has been selected for membership to the American Society of Clinical Investigation and the Association of American Physicians.

    Headquarters

    Theratechnologies inc.
    2015 Peel Street, 11th Floor
    Montréal, Québec
    Canada H3A 1T8
    Phone: 514 336-7800
    Fax: 514 331-9691

    European Headquarters

    Theratechnologies Europe Limited
    2 Hume Street, 4th floor
    Dublin 2
    Ireland D02 DV24
    Phone: +353 1 215 0650
    europe@theratech.com

    Investor Relations

    Elif McDonald
    Senior Director, Investor Relations
    Phone: +1-438-315-8563
    ir@theratech.com

    US Headquarters

    Theratechnologies U.S., Inc.
    101 Hudson Street
    21st Floor
    Jersey City, New Jersey 07302

    Main Nav

    • Home
    • About
    • Medicines & Pipeline
    • Investors
    • Corporate Responsibility
    • Careers
    • Contact Us
    ©2023 - Theratechnologies Inc.

    Legal Nav

    • Terms of Use
    • Privacy

    Search

    Theratechnologies